Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Sutro Biopharma, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 63 | 2 | 78 | +17 |
| Shares | 5.60M | 375.8K | 14.4M | +9.16M (+175.4%) |
| Value | $64.8M | $4.35M | $358.3M | +$297.9M (+492.8%) |
2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (26)
Institutions that held Sutro Biopharma, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
Sold out (9)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vestal Point Capital, LP | 243,000 | $2.81M |
| Tang Capital Management LLC | 139,617 | $1.62M |
| Spruce Street Capital LP | 75,594 | $874.6K |
| Shay Capital LLC | 24,255 | $280.6K |
| Two Sigma Advisers, LP | 17,580 | $203.4K |
| JPMorgan Chase & Co | 741 | $8.57K |
| Wells Fargo & Company | 100 | $1.16K |
| Essential Partners LLC | 4 | $46 |
| Group One Trading, L.P. | 2 | $23 |
Not filed for Q1 2026 yet (2)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 375,786 | $4.35M |
| Comerica Bank | 3 | $35 |